ERBB2 and neoplasm: In contrast, HER-2 expression has been described in 43.7% of cases and is considered an independent prognostic factor, as it is correlated with an increased risk grade of GIST, tumor size, mitotic count, and tumor relapse (Abd El-Aziz et al., 2017).